MHRAsafety guidance54% confidence
Research: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findings
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as Bayer.
Regulatory Analysis
Findings from the National Commission into the Regulation of AI in Healthcare's call for evidence and wider research and engagement activities.
Supporting Context
- Therapeutic area
- Cardiology · Pulmonary Hypertension
- Sub-indication
- Hypertension
Related signal: FDA Accepts Supplement for ADEMPAS (Riociguat) by Bayer Healthcare